Lung Non-Small Cell Carcinoma — Trials

Lung Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

6,742 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,746
Recruiting: 924
Ph III recruiting: 138
Growth YoY: +2.3%
Industry share: 44%
Top sponsor: AstraZeneca
Termination share: 39%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,044)

clinicaltrialsPublishedShowing 1–50 of 3,010 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03412877	Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer	recruiting	Phase 2	285	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT04405401	Stereotactic Ablative Radiotherapy for Oligo-Progressive Non Small Cell Lung Cancer(SUPPRESS-NSCLC)	terminated	Phase 2	52	Centre hospitalier de l'Université de Montréal (CHUM)OTHER